AURA insider trading
HealthcareAura Biosciences, Inc.: insider trade history from SEC Form 4 filings.
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Company website: www.aurabiosciences.com
AURA insider activity at a glance
FilingIQ tracks 136 insider transactions for AURA in filings since Oct 29, 2021. The most recent transaction is dated Sep 1, 2026.
Across the full history, 29 open-market purchases
and 40 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AURA insider trades is 48.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AURA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AURA?
- FilingIQ tracks 136 Form 4 insider transactions for AURA (Aura Biosciences, Inc.), covering filings from Oct 29, 2021 onwards. 5 of those are dated within the last 90 days.
- Are AURA insiders net buyers or net sellers?
- Across the full Form 4 history for AURA, 29 transactions (21%) were open-market purchases and 40 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AURA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AURA in?
- Aura Biosciences, Inc. (AURA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $333.39M.
Methodology & sources
Every AURA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.